FOLH1 and pachyonychia congenita: PSMA-targeted radioligand therapy (PSMA-RLT) using β- and α-emitters, such as 177Lu- and 225Ac-labeled PSMA-617 and PSMA-I&T, allows selective irradiation of PSMA-expressing prostate cancer (PC) cells and is used in many centers worldwide [2,3,4,5,6,7,8] and results of the first prospective phase 3 trial (VISION; NCT03511664) are anticipated [9].